

Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills

Robert F. Casper, M.D.

Division of Reproductive Sciences, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, and TRIO Fertility, Toronto, Ontario, Canada

For decades, combined estrogen-progestin oral contraceptive pills (OCPs) have been the first-line treatment for menstrual and pelvic pain associated with endometriosis without any clinical evidence of efficacy. Initial relief provided by OCPs is likely a result of improvement in primary dysmenorrhea. Biologic data and limited clinical evidence support a potential adverse effect of long-term use of OCPs on the progression of endometriosis. In contrast, there is randomized, controlled trial data to support the use of oral progestin-only treatment for pelvic pain associated with endometriosis and for suppressing the anatomic extent of endometriotic lesions. Both norethindrone acetate and dienogest have regulatory approval for treating endometriosis and may be better than OCPs as a first-line therapy. (Fertil Steril® 2017;107:533–6. ©2017 by American Society for Reproductive Medicine.)

Key Words: Dienogest, endometriosis, norethindrone acetate, oral contraceptives, progestins

Discuss: You can discuss this article with its authors and with other ASRM members at <https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/14320-23361>

Combined estrogen-progestin oral contraceptive pills (OCPs) have been used for decades as the first-line treatment for endometriosis despite an absence of controlled data regarding their effectiveness. In my opinion, based on assessment of the scientific and clinical data, OCPs should be supplanted by oral progestin-only therapy as the first line of treatment for chronic pelvic pain associated with endometriosis. Readers should note that my opinion in this regard runs contrary to the guidelines for the management of endometriosis from every gynecologic society, including the American College of Ob-

stetrics and Gynecology (ACOG), the American Society for Reproductive Medicine (ASRM), the European Society for Human Reproduction and Endocrinology (ESHRE), and the Canadian Fertility and Andrology Society (CFAS) (1–4), all of whom regard OCPs as the initial treatment option for endometriosis-associated pelvic pain and dysmenorrhea not responsive to nonsteroidal anti-inflammatories. My opinion is also in conflict with the recent comprehensive review published by Vercellini et al. (5) in which they suggested that combined estrogen and progestin should be the first-line therapy of endometriosis pain, followed by

progestin-only treatment in the case of a contraindication to estrogen.

Oral contraceptive pills are an intuitive choice for treatment of pain associated with endometriosis. In women with primary dysmenorrhea, OCPs thin the endometrium, thereby reducing the amount of bleeding and inhibiting the metabolism of arachidonic acid to prostaglandins (6, 7), effectively relieving cramping and pain. Because endometriotic implants have the morphologic appearance of endometrium, containing both epithelial glands and stroma, the natural assumption is that OCPs will have the same effect of decreasing the growth of implants as they do with eutopic endometrium. This assumption may not be correct, as I will explain later. In addition, OCPs generally have a high safety level and are inexpensive, and most family doctors and general gynecologists feel comfortable prescribing them. Patients also have a high comfort level with

Received November 9, 2016; revised January 1, 2017; accepted January 6, 2017; published online February 2, 2017.

R.F.C. reports personal fees from Abbvie, Bayer, EMD-Serono, Ferring, Merck, OvaScience, Fertility Nutraceuticals, and Inception-Lifebank; owns stock from OvaScience and Circadian-Zirclight; and is a medical director at Inception-Lifebank.

Reprint requests: Robert F. Casper, M.D., 655 Bay Street, Suite 1101, Toronto, Ontario M5G2K4, Canada (E-mail: casper@lunenfeld.ca).

Fertility and Sterility® Vol. 107, No. 3, March 2017 0015-0282/\$36.00
Copyright ©2017 American Society for Reproductive Medicine, Published by Elsevier Inc.
<http://dx.doi.org/10.1016/j.fertnstert.2017.01.003>

OCPs because many of their friends may be taking them for birth control or even for painful periods with good success. In addition, OCPs can be used to stop periods if given continuously. Based on this anecdotal evidence, OCPs have been used (off label) for decades to treat endometriosis.

Surprisingly, only one randomized, placebo-controlled clinical trial has ever been published to investigate the effectiveness of OCPs for pelvic pain and dysmenorrhea in patients with endometriosis (8). In this study, 100 women were randomized to an OCP or placebo, and a statistically significant though modest improvement was found in dysmenorrhea with OCP administration for 4 months when compared with placebo. The OCP resulted in about a 50% reduction in dysmenorrhea as determined by linear analogue pain scoring (shown in Fig. 1). One could argue that all the improvement in pain may be attributed to the reduction of primary dysmenorrhea (PG-related), which may still occur in women with endometriosis, without any effect on the pain associated with endometriosis. This speculation is supported by the lack of any beneficial effect of the OCP on non-menstrual pelvic pain and dyspareunia in these endometriosis patients (8).

There are other, relatively old, noncontrolled studies of OCPs in the treatment of pelvic pain and dysmenorrhea in women with documented endometriosis, and these show that about 50% of patients have partial or no improvement in symptoms (9). Of interest, an international study of women's perception of pain and bleeding in endometriosis enrolled 441 women between the ages of 15 to 49 years in eight countries, including Canada and the United States (10). The women were interviewed using an online questionnaire. The responses about OCP use by patients with diagnosed endometriosis demonstrated that about 70% of women had used multiple OCPs for relief of endometriosis pain and over 40% had been prescribed between 3 and 10 different OCPs for endometriosis (Table 1). These data suggest that there was recurrence of pelvic


pain while taking an OCP and that the patients were switched to a different OCP in the hope of alleviating the pain. This further supports the concept that OCP use is not completely effective in the treatment of endometriosis. Furthermore, switching from one OCP to another because of ineffectiveness of pain relief may lead to a delay in the diagnosis of endometriosis. Nevertheless, OCPs have remained the first line of treatment for endometriosis pain.

Why might an OCP be relatively ineffective in diminishing the activity of endometriosis implants when it is so effective in thinning the eutopic endometrium? Basic research findings suggest the answer to this question, and these studies are summarized nicely in two review articles by Bulun et al. (11, 12). In normal eutopic endometrium, estrogen in the follicular phase acts through the estrogen receptor (ER) to increase transcription and protein levels of the progesterone receptor (PR), especially the PR-B isoform (13). During the luteal phase, progesterone acts through PR-B to down-regulate ER and increase the transcription and secretion of the enzyme 17 β -hydroxysteroid dehydrogenase type 2 (HSD17B2) (12), which catalyzes the conversion of estradiol to the less active estrone. This effect is transcriptionally regulated by downstream PR-B signaling involving retinoic acid and Sp1/Sp3-dependent pathways (14). In endometriotic implants, ER- α is reduced but ER- β activity is markedly up-regulated (15, 16), leading to complete loss of PR-B (17) and the inability to induce HSD17B2 (12). Endometriosis implants, therefore, demonstrate resistance to progesterone and have augmented estrogen activity.

Low-dose OCPs contain 20 to 30 μ g of ethinyl estradiol (EE). Basic research (18) and data from clinical menopausal hormone therapy (19) suggest that 5 μ g of EE is equivalent to about 1 mg of micronized estradiol or 0.625 mg of conjugated equine estrogen. Therefore, the dose of EE in a low-dose OCP is equivalent to 4 to 6 times the physiologic dose of estrogen. The OCPs also contain a progestin designed to antagonize the estrogen effect on the endometrium. Based on the previously described evidence for ER and PR alterations in endometriosis, it is likely that administering a high dose of estrogen and progestin in an OCP is counterproductive, resulting in estrogen dominance in the presence of progesterone resistance. In fact, based on their review of earlier work by Dizerega et al. (20), Vercellini et al. (21) suggested that the presence of supraphysiologic concentrations of estrogen with the OCP, during what should be the low-estrogen menstrual phase, may rescue endometrial cell clusters deposited in the pelvis during retrograde menses.

There are other, albeit limited, data suggesting an adverse effect of OCPs on endometriosis. A recent meta-analysis looked at the risk of developing endometriosis in women who were current or past users of OCPs. The investigators showed a reduced risk of endometriosis in current users of OCPs but an increase in endometriosis risk in past users of OCPs (21). Chapron et al. (22) also reported an increased incidence of endometriosis in past users of OCPs. It may seem incongruous that there is an observed increased risk of endometriosis in past but not present users of OCPs. However, this finding is consistent with the fact that the large majority of women currently using OCPs are taking them for

FIGURE 1



Changes in mean dysmenorrhea score determined by linear analogue scale comparing an oral contraceptive pill (OCP) with placebo. Source: Harada et al. 2008 (8). Copyright Elsevier, and the American Society for Reproductive Medicine.

Casper. Progestin-only pills for endometriosis. *Fertil Steril* 2017.

Download English Version:

<https://daneshyari.com/en/article/5690016>

Download Persian Version:

<https://daneshyari.com/article/5690016>

[Daneshyari.com](https://daneshyari.com)